[1]
Abramsky, L. and Chapple, J. 2003. Prenatal diagnosis: the human side. Nelson Thornes.
[2]
Agathokleous, M. et al. 2013. Meta-analysis of second-trimester markers for trisomy 21. Ultrasound in Obstetrics & Gynecology. 41, 3 (Mar. 2013), 247–261. DOI:https://doi.org/10.1002/uog.12364.
[3]
Alessandra Cacciatore 2009. Obstetric management in Rh alloimmunizated pregnancy. Journal of Prenatal Medicine. 3, 2 (2009).
[4]
American Association for Clinical Chemistry Clinical chemistry.
[5]
Barrett, A.N. et al. 2012. Digital PCR Analysis of Maternal Plasma for Noninvasive Detection of Sickle Cell Anemia. Clinical Chemistry. 58, 6 (Jun. 2012), 1026–1032. DOI:https://doi.org/10.1373/clinchem.2011.178939.
[6]
Benn, P.A. 2009. Practical and Ethical Considerations of Noninvasive Prenatal Diagnosis. JAMA. 301, 20 (May 2009). DOI:https://doi.org/10.1001/jama.2009.707.
[7]
Bianchi, D.W. et al. 2012. Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing. Obstetrics & Gynecology. 119, 5 (May 2012), 890–901.
[8]
Celik, E. et al. 2008. Cervical length and obstetric history predict spontaneous preterm birth: development and validation of a model to provide individualized risk assessment. Ultrasound in Obstetrics and Gynecology. 31, 5 (May 2008), 549–554. DOI:https://doi.org/10.1002/uog.5333.
[9]
Chitty, L.S. et al. 2008. SAFE—TheSpecial Non-invasiveAdvances inFetal and NeonatalEvaluation Network: aims and achievements. Prenatal Diagnosis. 28, 2 (Feb. 2008), 83–88. DOI:https://doi.org/10.1002/pd.1929.
[10]
Chudleigh, P. and Thilaganathan, B. 2004. Obstetric ultrasound: how, why and when. Elsevier Churchill Livingstone.
[11]
Deans, Z. et al. 2015. For Your Interest? The Ethical Acceptability of Using Non-Invasive Prenatal Testing to Test ‘Purely for Information’. Bioethics. 29, 1 (Jan. 2015), 19–25. DOI:https://doi.org/10.1111/bioe.12125.
[12]
Deprest, J. et al. 2016. In case you missed it: the editors bring you the most significant advances of 2015. Prenatal Diagnosis. 36, 1 (Jan. 2016), 3–9. DOI:https://doi.org/10.1002/pd.4758.
[13]
European Society of Human Genetics European journal of human genetics: EJHG.
[14]
Gallo, D. et al. 2014. Prediction of Preeclampsia by Mean Arterial Pressure at 11-13 and 20-24 Weeks’ Gestation. Fetal Diagnosis and Therapy. 36, 1 (2014), 28–37. DOI:https://doi.org/10.1159/000360287.
[15]
Gallo, D.M. et al. 2013. Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks’ Gestation. Fetal Diagnosis and Therapy. 34, 4 (2013), 241–247. DOI:https://doi.org/10.1159/000356171.
[16]
Harrison, M.R. et al. 2001. The unborn patient: the art and science of fetal therapy. Saunders.
[17]
Hill, M. et al. 2012. Uses of cell free fetal DNA in maternal circulation. Best Practice & Research Clinical Obstetrics & Gynaecology. 26, 5 (Oct. 2012), 639–654. DOI:https://doi.org/10.1016/j.bpobgyn.2012.03.004.
[18]
International Fetal Medicine and Surgery Society Fetal diagnosis and therapy.
[19]
International Society for Prenatal Diagnosis Prenatal diagnosis. Wiley medical publication.
[20]
Massachusetts Medical Society The New England journal of medicine.
[21]
Milunsky, A. and Milunsky, J.M. eds. 2021. Genetic Disorders and the Fetus. John Wiley & Sons Ltd.
[22]
Nicolaides, K.H. 2011. Turning the Pyramid of Prenatal Care. Fetal Diagnosis and Therapy. 29, 3 (2011), 183–196. DOI:https://doi.org/10.1159/000324320.
[23]
Pandya, P.P. et al. eds. 2020. Fetal medicine: basic science and clinical practice. Elsevier.
[24]
Ravitsky, V. 2009. Non-invasive prenatal diagnosis: an ethical imperative. Nature Reviews Genetics. 10, 10 (Oct. 2009), 733–733. DOI:https://doi.org/10.1038/nrg2631-c1.
[25]
Sadler, T.W. 2015. Langman’s medical embryology. Wolters Kluwer.
[26]
Simpson, J.L. and Elias, S. 1993. Essentials of prenatal diagnosis. Churchill Livingstone.
[27]
Smith, N.C. et al. 2006. Obstetric and gynaecological ultrasound made easy. Elsevier Churchill Livingstone.
[28]
Sparks, A.B. et al. 2012. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenatal Diagnosis. 32, 1 (Jan. 2012), 3–9. DOI:https://doi.org/10.1002/pd.2922.
[29]
Syngelaki, A. et al. 2011. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenatal Diagnosis. 31, 1 (Jan. 2011), 90–102. DOI:https://doi.org/10.1002/pd.2642.
[30]
Syngelaki, A. et al. 2014. Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities. Fetal Diagnosis and Therapy. 35, 3 (2014), 174–184. DOI:https://doi.org/10.1159/000358388.
[31]
Wald, N.J. and Bestwick, J.P. 2015. Performance of antenatal reflex DNA screening for Down’s syndrome. Journal of Medical Screening. 22, 4 (Dec. 2015), 168–174. DOI:https://doi.org/10.1177/0969141315581005.
[32]
Wright, C.F. and Burton, H. 2008. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update. 15, 1 (Oct. 2008), 139–151. DOI:https://doi.org/10.1093/humupd/dmn047.
[33]
1987. Baillière’s Clinical Obstetrics and Gynaecology. 1, 3 (1987).
[34]
1975. Journal of Medical Ethics. (1975).
[35]
Journal of Prenatal Medicine.
